TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01595763

Intervention type: OTHER
Intervention: D Dimer and ultrasonography
Description: clinical history, Dimer D, ultrasonography
Study: NCT03051932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofiramev® (IV Acetaminophen)
Description: Post -op pain medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV administration
Description: Post -op pain
Study: NCT01837524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KP Personal Shopper Visits
Description: Testing co-shopping visits conducted in the grocery store (1:1 visits with dietitian while grocery shopping) versus in-office visits which are the current standard of care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Office Dietitian Visits
Description: Participants will have 3, 1 hour in-office sessions with the dietitian during which targeted curriculum on nutritional knowledge, weight management, healthier eating, menu and label reading, will be delivered. These visits will take place monthly over a three month period.
Study: NCT05546463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital games
Description: A digital game was played via iPad Air 2 32GB 9.7-inch wi-fi model tablet. The researcher created a folder with a range of selected games to appeal to different preferences. Children could choose from the following games: Word Travel, Talking Tom Candy Run, 384 Puzzles for Kids, Masha and The Bear, Subway Surfers, Head Ball 2 and Dream League Soccer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital games
Description: A digital game was played via iPad Air 2 32GB 9.7-inch wi-fi model tablet. The researcher created a folder with a range of selected games to appeal to different preferences. Children could choose from the following games: Word Travel, Talking Tom Candy Run, 384 Puzzles for Kids, Masha and The Bear, Subway Surfers, Head Ball 2 and Dream League Soccer.
Study: NCT01318135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and metformin
Description: Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
Study: NCT03976024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DHBN-FN arm
Description: DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index
Study: NCT04467060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium
Description: 2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 120mg, 160mg，fasting oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose, fasting oral administration
Study: NCT04432324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: SMT
Study: NCT04660006

Intervention type: PROCEDURE
Intervention: Cataract surgery
Description: Patients undergoing uneventful cataract surgery were recruited to this study if they met the inclusion criteria of the three groups. Postoperative retinal vasculature measures, as recorded by the optical coherence tomography angiography imaging technique, were compared to baseline measures.

Intervention type: PROCEDURE
Intervention: Cataract surgery
Description: Patients undergoing uneventful cataract surgery were recruited to this study if they met the inclusion criteria of the three groups. Postoperative retinal vasculature measures, as recorded by the optical coherence tomography angiography imaging technique, were compared to baseline measures.

Intervention type: PROCEDURE
Intervention: Cataract surgery
Description: Patients undergoing uneventful cataract surgery were recruited to this study if they met the inclusion criteria of the three groups. Postoperative retinal vasculature measures, as recorded by the optical coherence tomography angiography imaging technique, were compared to baseline measures.
Study: NCT00194415

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safer-sex counseling
Description: Subjects will receive safer-sex counseling during pregnancy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Type specific serologic HSV testing
Description: Subjects will be testing for HSV by Western Blot
Study: NCT01863706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400µg oral misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 20 IU Oxytocin
Study: NCT01501734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: watch-pat
Description: The Watch-PAT is a home sleep testing (HST) device. The Watch-PAT is a patient-worn, self-contained, non-invasive device used in the patient's home.~The Watch-PAT diagnoses obstructive sleep apnea (OSA) by measuring the PAT signal, heart rate, oxygen saturation, and actigraphy. The PAT signal is a validated surrogate measure of sympathetic activation that is associated with apneic events and respiratory effort related arousals (RERA). The Watch-PAT provides measures of all the OSA indices, i.e., Apnea Hypopnea Index (AHI), Respiratory Disturbances Index (RDI), and Oxygen Desaturation Index (ODI), which enable accurate assessment of the presence and severity of OSA and its effect on sleep architecture, sleep quality.~Based on the PAT and actigraphy signals, Watch-PAT differentiates between sleep and wake and detects sleep stages (light, deep, and REM) providing, the effect on additional specific conditions such as REM related apnea.
Study: NCT02723019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteer Peer Mentor+Behavioral Health Nurse
Description: Intervention group participants receive intervention services from a Volunteer Peer Mentor and a Behavioral Health Nurse
Study: NCT04462978

Intervention type: OTHER
Intervention: Non IgE-mediated food allergy
Study: NCT00724646

Intervention type: OTHER
Intervention: Survey
Description: 3 individual surveys

Intervention type: OTHER
Intervention: Survey
Description: 3 individual surveys

Intervention type: OTHER
Intervention: Focus group
Description: Focus group discussions facilitated by a psychologist
Study: NCT03150615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Description: Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament. Standard enteral diet, administered through a nasojejunal tube, is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.~After PD, enteral nutrition liquid regimen will be used step by step from postoperative day 1 to postoperative day 7.Patients are targeted to receive calories for 25 kcal/kg/day. Meanwhile, oral food intake was not restricted.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament.~After PPPD,Only Normal Saline were given through nasojejunal tube. Entral nutrition was not administrated. Patients intake food orally at will.

Intervention type: DEVICE
Group type: OTHER
Intervention: nasojejunal tube insertion
Study: NCT03976024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm (Erysipelas)
Description: The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission).
Study: NCT02402205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TF-CBT
Description: Web TF-CBT implementation or Web + Live TF-CBT implementation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TF-CBT
Description: Web TF-CBT implementation or Web + Live TF-CBT implementation
Study: NCT00969306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine, A-CQ 100
Description: Administration:~* Orally~* Timing: Once daily~* Tablets of 100 mg~* During or after meals~* In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.~* Patients should always note date and time of intake on the chloroquine monitoring form.
Study: NCT04829786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palovarotene low-dose
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palovarotene low-dose
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palovarotene high-dose
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palovarotene high-dose
Description: oral capsules
Study: NCT01003236

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 140 mg placebo tablets, 3 times per day for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Thistle extract
Description: 1 tablet equal to 140mg silymarin administered 3 times a day for 3 months
Study: NCT01749124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: My Coach Connect
Description: Clients will call in to the system approximately twice a week for a period of four months. The study will be conducted in two phases. There will be an initial pilot phase where we will seek to enroll approximately 15-20 patients and 2-3 providers. This phase will last approximately two months and the goal will be to assess feasibility and obtain feedback on the tool and surveys to optimize them for this setting. We will begin the main phase of the study approximately one month after the end of the first phase and in that study seek to recruit approximately 150 patients and 5-10 providers from the ROADS program. Clients enrolled in this main phase of the study will enroll for a period of four months.
Study: NCT04611347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: Topical CBD application for thumb basal joint osteoarthritis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: Topical CBD application for thumb basal joint osteoarthritis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shea Butter
Description: Placebo Shae Butter for comparison

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shea Butter
Description: Placebo Shae Butter for comparison
Study: NCT02659033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: ceftriaxone (1 gram per day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefotaxime
Description: cefotaxime (1 gram every 8 hours)
Study: NCT03235895

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational material
Description: Educational material given as a part of CME activity as through enhanced internet method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational material
Description: Educational material given as a part of CME activity as through enhanced internet method
Study: NCT04148066

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ctDNA blood sample
Description: every six weeks during treatment and upon radiological progression blood will be drawn to analyse ctDNA with Avenio ctDNA (Expanded panel) to detect all known EGFR TKI resistance mechanisms.
Study: NCT03150615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasojejunal tube insertion

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: nasojejunal tube insertion

Intervention type: OTHER
Group type: OTHER
Intervention: Oral intake
Description: Patients was encouraged to drink water on postoperative day 1, to eat liquid diet on postoperative day 2, to eat semi-solid on postoperative day 3, to eat solid food on postoperative day 4.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral intake
Description: Patients was encouraged to drink water on postoperative day 1, to eat liquid diet on postoperative day 2, to eat semi-solid on postoperative day 3, to eat solid food on postoperative day 4.
Study: NCT00883805

Intervention type: BIOLOGICAL
Intervention: Blood draw
Description: Subjects will give blood for analysis of metal ion concentrations

Intervention type: BIOLOGICAL
Intervention: Blood draw
Description: Subjects will give blood for analysis of metal ion concentrations

Intervention type: RADIATION
Intervention: X-Ray of Hip
Description: Subject will have x-ray of hip to assessment of osteolysis

Intervention type: RADIATION
Intervention: X-Ray of Hip
Description: Subject will have x-ray of hip to assessment of osteolysis
Study: NCT00724646

Intervention type: OTHER
Intervention: Focus group
Description: Focus group discussions facilitated by a psychologist
Study: NCT02756845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Talimogene laherparepvec will be administered by intralesional injection only into injectable cutaneous, subcutaneous, nodal tumors, and other non-visceral tumors with or without image ultrasound guidance. The first dose of talimogene laherparepvec will be up to 4.0 mL of 10\^6 PFU/mL administered on day 1. The second injection, up to 4.0 mL of 10\^8 PFU/mL (or up to 4.0 mL of 10\^6 PFU/mL for a dose de-escalated cohort), will be administered 21 (+3) days after the initial injection. All subsequent injections, up to 4.0 mL of 10\^8 PFU/mL (or up to 4.0 mL of 10\^6 PFU/mL for a dose de-escalated cohort), will be administered every 14 (± 3) days. The treatment cycle interval may be increased due to toxicity.
Study: NCT04246424

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fibit + Coaching
Description: This intervention is a combination of the coaching and fitbit interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: Coaching Participants who are assigned coaching group will receive telephone coaching. Coaches follow a guide developed by Kelly Glazer Baron, Jennifer Duffecy, Kathryn Reid, and Lauren Caccamo. The first session is an approximately 30 minute engagement session, with the purpose of getting to know the participant to increase likelihood for participation. The end goal is to have participants express Desire, Ability, Reason, Need, Can (DARN-C) to make changes in sleep). The remainder calls (week 2-6) are follow-up calls lasting about 5 minutes. The goal of these calls is to keep participants motivated and address any issues with the Fitbit hard or software.~Participants will also receive weekly email lessons to their personal email address for 1-6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Fitbit Participants in the fitbit group will receive a Fitbit Charge 3 black, and asked to wear it for 1-6 weeks. Participants will monitor their sleep through the sleep section in the Fitbit app on the smartphone. Participants will be provided login information so that researchers can access this data and asked to keep Bluetooth on. After week 6, participants can choose to continue to wear the device for the duration of the study (12 weeks). Though wear at weeks 7-12 is not required, researchers will still use any data that was collected from the fitbit during that time. At the completion of their participation, researchers retain the login information and the device is switched to a personal login of the participants choice.
Study: NCT00513370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humira (adalimumab)
Description: Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.
Study: NCT04942444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: One-hour weekly session of DN in the 18th tender points during 6 weeks in the DNG, apart from continuing their medical treatment. The CG continue with the habitual medical treatment.
Study: NCT01738360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: The study duration was 30 months (24 months recruitment + 6 months follow-up).Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day). The treatment should be administered by IV infusion over 2 hours of D1 to D4 (conventional hospitalization) and at D8, D11, D15, D18, D22 and D25. The protocol starts at the dose of 0.10 mg / kg / day. The stage at the dose of 0.075mg/kg/day is planned in case of toxicity with the first stage at the dose of 0.10mg/kg/day.~The course of study is as follows :~* Pre-inclusion between D-35 and D-15~* Ten injections during the first month distributed as follows : conventional hospitalization from D1 to D4 (one injection per day) and daily hospitalization day for injections at D8, D11, D15, D18, D22 and D25.~* A telephone contact between D32 and D34~* A consultation at D40 then monthly consultation at D60, D90, D120, D150 and D180
Study: NCT02601690

Intervention type: OTHER
Intervention: Blood Sampling
Study: NCT03933345

Intervention type: OTHER
Intervention: Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control.
Description: At enrollment, participants will complete a detailed survey instrument establishing histories of substance use, naloxone exposure, and other potential barriers to the uptake of naloxone training. Because extant research establishes a clear public health and ethical imperative to provide PWUIO with naloxone, we will also offer all participants training to become naloxone-equipped OD responders at enrollment. We will follow the sample for two years using a mixed-methods approach involving text-message-based exposure tracking, monthly surveys using a state-of-the-art online data collection portal, and a qualitative subsample to ensure that naloxone exposures and changes in OD risk behavior are carefully tracked and contextualized by ethnographic data about the psychosocial and sociocultural mechanisms underlying participant experiences.
Study: NCT03202498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4g Yaq-001
Description: Study patients will be dosed daily with 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
Study: NCT01328769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01834950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test
Study: NCT01492166

Intervention type: DRUG
Intervention: biphasic human insulin 30
Description: Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines
Study: NCT03136913

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoplast® TXT-200
Description: Non-resorbable membrane

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoplast® TXT-200
Description: Non-resorbable membrane

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MinerOss® Cortical and Cancellous Chips (FDBA)
Description: Mixture of allograft mineralized cortical and cancellous chips

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MinerOss® Cortical and Cancellous Chips (FDBA)
Description: Mixture of allograft mineralized cortical and cancellous chips

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flap Technique
Description: After extraction, the socket wound is left open to heal by secondary intention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Flap Technique
Description: After extraction, the socket wound is closed by primary closure
Study: NCT01364142

Intervention type: PROCEDURE
Intervention: endobronchial blocker
Description: After intubation of endotracheal tube, the Uniblocker® was inserted into the endotracheal tube and advanced step by step with inflation of the blocker balloon until the peak inspiratory pressure dropped abruptly.
Study: NCT00529412

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seprafilm
Description: two sheets per body

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Seprafilm
Description: two sheets per body
Study: NCT00072046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10mg/kg IV infusion on Days 1 \& 15 of each cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: 9 million units subQ injection 3 x/week for 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: 9 million units subQ injection 3 x/week for 4 weeks
Study: NCT00802724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classification-directed treatment
Description: People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-specific treatment
Description: People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
Study: NCT05848336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten Free Casein Free Diet
Description: Thirty children with autism were evaluated before the diet (Pre-Test) and after 8 weeks of dietary intervention (Post-Test).
Study: NCT02950441

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03437993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recollect, the game
Description: Recollect is a working memory training game

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Tetris
Description: App-based video game where shapes are rotated and placed to fit a grid